Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03244072

Enrollment

60000

Registered

2017-08-09

Start date

2027-06-01

Completion date

2031-10-01

Last updated

2026-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endophthalmitis

Brief summary

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Detailed description

Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.

Interventions

DRUGMoxifloxacin

Intracameral injection

DRUGPlacebo

intracameral injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* visually significant cataracts

Exclusion criteria

* allergy to fluoroquinolones, cobalamin (B12)

Design outcomes

Primary

Measure	Time frame	Description
Endophthalmitis after cataract surgery	Subjects will undergo eye examinations at one day, one week, and one month post-operatively	Subjects will be followed after cataract surgery and have post-operative eye examinations to determine if infection in the eye (endophthalmitis) occurs during the study period.

Countries

United States

Contacts

CONTACTJason Ahee, M.D.

aheejason@hotmail.com435-862-9865

PRINCIPAL_INVESTIGATORJason Ahee, M.D.

Zion Therapeutics, LLC

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 16, 2026